Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Huot

Showing results (81-90 of 107) with videos related to

Pageof 11
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|March 16, 2012
Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's diseasePhilippe Huot, Tom H Johnston, Naomi P Visanji, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 15, 2010
Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinationsPhilippe Huot, Tom H Johnston, Tayyeba Darr, et al.
Neuropharmacology|July 29, 2019
Activation of mGlu<sub>2/3</sub> receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonismImane Frouni, Adjia Hamadjida, Cynthia Kwan, et al.
Psychopharmacology|January 29, 2017
The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmosetAdjia Hamadjida, Stephen G Nuara, Nicolas Veyres, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|July 6, 2023
The mGluR<sub>2/3</sub> orthosteric agonist LY-404,039 reduces dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmosetWoojin Kang, Stephen G Nuara, Dominique Bédard, et al.
European Journal of Pharmacology|February 1, 2020
Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmosetLamia Sid-Otmane, Adjia Hamadjida, Stephen G Nuara, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 13, 2011
Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-timePhilippe Huot, Tom H Johnston, Katie D Lewis, et al.
Movement Disorders Clinical Practice|October 10, 2024
Sex Differences in Neuropsychiatric Symptoms in Alpha-Synucleinopathies: A Systematic Review and Meta-AnalysisVincent Couture, Jean-François Carmel, Katerine Rousseau, et al.
Neuropharmacology|January 23, 2014
UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmosetPhilippe Huot, Tom H Johnston, Katie D Lewis, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 30, 2015
Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in FranceAlain Toledano, Elisabeth Luporsi, Jean François Morere, et al.
Pageof 11

Showing results (81-90 of 107) with videos related to

Sort By:
Pageof 11
Movement Disorders : Official Journal of the Movement Disorder Society|March 16, 2012
Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's diseasePhilippe Huot, Tom H Johnston, Naomi P Visanji, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 15, 2010
Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinationsPhilippe Huot, Tom H Johnston, Tayyeba Darr, et al.
Neuropharmacology|July 29, 2019
Activation of mGlu<sub>2/3</sub> receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonismImane Frouni, Adjia Hamadjida, Cynthia Kwan, et al.
Psychopharmacology|January 29, 2017
The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmosetAdjia Hamadjida, Stephen G Nuara, Nicolas Veyres, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|July 6, 2023
The mGluR<sub>2/3</sub> orthosteric agonist LY-404,039 reduces dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmosetWoojin Kang, Stephen G Nuara, Dominique Bédard, et al.
European Journal of Pharmacology|February 1, 2020
Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmosetLamia Sid-Otmane, Adjia Hamadjida, Stephen G Nuara, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 13, 2011
Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-timePhilippe Huot, Tom H Johnston, Katie D Lewis, et al.
Movement Disorders Clinical Practice|October 10, 2024
Sex Differences in Neuropsychiatric Symptoms in Alpha-Synucleinopathies: A Systematic Review and Meta-AnalysisVincent Couture, Jean-François Carmel, Katerine Rousseau, et al.
Neuropharmacology|January 23, 2014
UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmosetPhilippe Huot, Tom H Johnston, Katie D Lewis, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 30, 2015
Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in FranceAlain Toledano, Elisabeth Luporsi, Jean François Morere, et al.
Pageof 11